Last updated: 11/04/2018 04:31:56
Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Phase III study of Adefovir Dipivoxil tablets in patients with compensated chronic hepatitis B -Comparative study against Lamivudine-
Trial description: This study is designed to compare the efficacy and safety of adefovir dipivoxil 10 mg with lamivudine 100 mg in Japanese patients with compensated chronic hepatitis B over 52-week periods.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Mean Change from Baseline in Hepatitis B Virus (HBV) DNA at Week 52
Timeframe: Baseline and Week 52
Secondary outcomes:
Percentage of participants with HBV DNA Loss (<400 copies/mL) at Week 52
Timeframe: Week 52
Time to onset of HBV DNA loss (< 400 copies/mL)
Timeframe: From Baseline to Week 52
Percentage of participants with Hepatitis B e antigen (HBeAg) loss at Week 52
Timeframe: Week 52
Percentage of participants with Hepatitis B e antigen/antibody (HBeAg/Ab) Seroconversion at Week 52
Timeframe: Week 52
Time to onset of HBeAg loss
Timeframe: From Baseline to Week 52
Time to onset of HBeAg/Ab seroconversion
Timeframe: From Baseline to Week 52
Percentage of participants with Hepatitis B s antigen (HBsAg) loss at Week 52
Timeframe: Week 52
Percentage of participants with Hepatitis B s antigen/ antibody (HBsAg/Ab) Seroconversion at Week 52
Timeframe: Week 52
Mean alanine aminotransferase (ALT) level at Week 52
Timeframe: Week 52
Percentage of participants with alanine aminotransferase (ALT) normalization at Week 52
Timeframe: Week 52
Time to onset of ALT normalization
Timeframe: From Baseline to Week 52
Rate of Emergence of Resistant Virus at Week 52
Timeframe: Week 52
Interventions:
Enrollment:
105
Primary completion date:
2008-16-01
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Chronic Hepatitis B
Product
adefovir
Collaborators
Not applicable
Study date(s)
January 2006 to January 2008
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
16 - 64 years
Accepts healthy volunteers
No
- Inclusion criteria:
- Have compensated chronic hepatitis B.
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion criteria:
- Have compensated chronic hepatitis B.
- Have not been treated with anti HBV agents with antiproliferative activity against. However, previous Interferon (IFN) therapy is permitted.
- Ability to read, understand, and sign the informed consent.
- Have a positive serum HBV-DNA >= 1,000,000 copies/mL and ALT level 50-500 U/L Exclusion criteria:
- Having or suspected of having liver cancer.
- Co-infected with Hepatitis C virus (HCV) or Human Immunodeficiency virus (HIV).
- Autoimmune hepatitis.
- Received any previous transplantation or having a plan for any transplantation.
- Existence of any serious complication, except hepatitis B.
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2008-16-01
Actual study completion date
2008-16-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website